Arcutis Biotherapeutics (ARQT) Projected to Post Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is projected to release its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.09) per share and revenue of $86.6910 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $72.70 million. Arcutis Biotherapeutics had a negative net margin of 35.40% and a negative return on equity of 62.62%. On average, analysts expect Arcutis Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcutis Biotherapeutics Stock Up 0.1%

Arcutis Biotherapeutics stock opened at $20.11 on Monday. The company has a market cap of $2.41 billion, a P/E ratio of -26.81 and a beta of 2.06. Arcutis Biotherapeutics has a 1-year low of $8.21 and a 1-year high of $21.84. The company has a fifty day simple moving average of $18.11 and a 200 day simple moving average of $15.58. The company has a current ratio of 3.20, a quick ratio of 3.04 and a debt-to-equity ratio of 0.77.

Insider Activity at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $18.92, for a total transaction of $189,200.00. Following the completion of the sale, the director owned 99,744 shares in the company, valued at approximately $1,887,156.48. This trade represents a 9.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Larry Todd Edwards sold 4,504 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $20.04, for a total transaction of $90,260.16. Following the sale, the insider owned 178,897 shares of the company’s stock, valued at approximately $3,585,095.88. This represents a 2.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,386 shares of company stock worth $2,640,187 in the last quarter. 9.40% of the stock is owned by corporate insiders.

Institutional Trading of Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning raised its stake in Arcutis Biotherapeutics by 8.2% in the 2nd quarter. Creative Planning now owns 19,575 shares of the company’s stock worth $274,000 after purchasing an additional 1,477 shares in the last quarter. Oxford Asset Management LLP raised its stake in Arcutis Biotherapeutics by 9.1% in the 2nd quarter. Oxford Asset Management LLP now owns 23,271 shares of the company’s stock worth $326,000 after purchasing an additional 1,947 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Arcutis Biotherapeutics by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after purchasing an additional 2,063 shares in the last quarter. E Fund Management Co. Ltd. raised its stake in Arcutis Biotherapeutics by 14.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 17,184 shares of the company’s stock worth $241,000 after purchasing an additional 2,197 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Arcutis Biotherapeutics by 38.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 11,653 shares of the company’s stock worth $163,000 after purchasing an additional 3,234 shares in the last quarter.

Analysts Set New Price Targets

ARQT has been the subject of a number of analyst reports. Cowen reaffirmed a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Thursday, August 7th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Needham & Company LLC raised their target price on shares of Arcutis Biotherapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Arcutis Biotherapeutics in a research report on Tuesday, October 14th. Finally, The Goldman Sachs Group assumed coverage on shares of Arcutis Biotherapeutics in a research note on Friday, July 25th. They issued a “neutral” rating and a $18.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.80.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.